Enhancing the cellular anti-proliferation activity of pyridazinones as c-met inhibitors using docking analysis

<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi et al. · Science · 2007 · 4.4K citations

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

Ravid Straussman, Teppei Morikawa, Kevin Shee et al. · Nature · 2012 · 1.7K citations · Full text

Tumor Biology, Micro-environment Elicits, Medicine +10

Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)

J. Jean Cui, Michelle Tran‐Dubé, Hong Shen et al. · Journal of Medicinal Chemistry · 2011 · 905 citations · Full text

Drug Target, Lead Series, Chemical Biology +20

Discovery of <i>N</i>-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of the Met Kinase Superfamily

Gretchen M. Schroeder, Yongmi An, Zhen‐Wei Cai et al. · Journal of Medicinal Chemistry · 2009 · 276 citations · Full text

Orally Efficacious Inhibitor, Drug Target, Pharmacotherapy +21

Targeting the Hepatocyte Growth Factor–cMET Axis in Cancer Therapy

George R. Blumenschein, Gordon B. Mills, Ana M. González-Angulo · Journal of Clinical Oncology · 2012 · 273 citations

Cancer Therapy, Tumor Biology, Gene Amplification +12